Biomimetic hydrogels for controlled biomolecule delivery to augment bone regeneration

Advanced Drug Delivery Reviews

Volumn 64, Issue 12, 2012, Pages 1078-1089

  Lienemann, Philipp S ^a,b   Lutolf, Matthias P ^b   Ehrbar, Martin ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b EPFL   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Biomimetic hydrogels; Bone; Controlled delivery; ECM mimicking; Growth factors

Indexed keywords

ADVERSE SIDE EFFECTS; AFFINITY BINDING; BIOMIMETIC HYDROGELS; BONE DEFECT; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CLINICAL PROBLEMS; CONTROLLED DELIVERY; COVALENT GRAFTING; DYNAMIC INTERACTION; ECM-MIMICKING; EXTRACELLULAR MATRICES; FUTURE TECHNOLOGIES; GOLD STANDARDS; GROWTH FACTOR; ORDERS OF MAGNITUDE; PHYSIOLOGICAL DOSE; PROTEIN THERAPEUTICS; SOLID-PHASE; TREATMENT COSTS;

BIOLOGICAL MATERIALS; BIOMATERIALS; BIOMOLECULES; DEFECTS;

BONE;

ACRYLIC ACID; ANGIOTENSIN I; APROTININ; BENZOTRIAZOLE DERIVATIVE; BIOMATERIAL; BONE DERIVED GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN; COPOLYMER; DIACRYLATE; DISSUCCINIMIDYLDIGLUTARATEPOLYETHYLENEGLYCOL; DISSUCCINIMIDYLDISUCCINATEPOLYETHYLENEGLYCOL; EPHRIN A1; EPHRIN B2; FIBROBLAST GROWTH FACTOR; KERATINOCYTE GROWTH FACTOR; MACROGOL; N HYDROXYSUCCINIMIDE; NERVE GROWTH FACTOR BETA SUBUNIT; PARATHYROID HORMONE; PLATELET DERIVED GROWTH FACTOR BB; POLYLACTIDE CO ETHYLENE OXIDE CO FUMARATE; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1ALPHA; SUCCINIMIDE DERIVATIVE; SUCCINIMIDYL TRANS 4 (MALEIMIDYLMETHYL)CYCLOHEXANE 1 CARBOXYLATE; SUCCINIMIDYLCARBONATE; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165;

BINDING AFFINITY; BIOMIMETICS; BONE GRAFT; BONE GROWTH; BONE REGENERATION; BONE REMODELING; COVALENT BOND; EXTRACELLULAR MATRIX; FRACTURE HEALING; HYDROGEL; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN IMMOBILIZATION; PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOMIMETICS; BONE AND BONES; BONE REGENERATION; BONE TRANSPLANTATION; EXTRACELLULAR MATRIX; HUMANS; HYDROGELS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 84865282959     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.03.010     Document Type: Review

References (170)

1. Bishop G.B., Einhorn T.A. Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int. Orthop. 2007, 31:721-727.
2. Castillo R.C., Bosse M.J., MacKenzie E.J., Patterson B.M. Impact of smoking on fracture healing and risk of complications in limb-threatening open tibia fractures. J. Orthop. Trauma 2005, 19:151-157.
3. Gandhi A., Liporace F., Azad V., Mattie J., Lin S.S. Diabetic fracture healing. Foot Ankle Clin. 2006, 11:805-824.
4. Gruber R., Koch H., Doll B.A., Tegtmeier F., Einhorn T.A., Hollinger J.O. Fracture healing in the elderly patient. Exp. Gerontol. 2006, 41:1080-1093.
5. Lu C., Hansen E., Sapozhnikova A., Hu D., Miclau T., Marcucio R.S. Effect of age on vascularization during fracture repair. J. Orthop. Res. 2008, 26:1384-1389.
6. Lynch J.R., Taitsman L.A., Barei D.P., Nork S.E. Femoral nonunion: risk factors and treatment options. J. Am. Acad. Orthop. Surg. 2008, 16:88-97.
7. Wukich D.K., Kline A.J. The management of ankle fractures in patients with diabetes. J. Bone Joint Surg. Am. 2008, 90:1570-1578.
8. Arrington E.D., Smith W.J., Chambers H.G., Bucknell A.L., Davino N.A. Complications of iliac crest bone graft harvesting. Clin. Orthop. Relat. Res. 1996, 300-309.
9. Sasso R.C., Williams J.I., Dimasi N., Meyer P.R. Postoperative drains at the donor sites of iliac-crest bone grafts. A prospective, randomized study of morbidity at the donor site in patients who had a traumatic injury of the spine. J. Bone Joint Surg. Am. 1998, 80:631-635.
10. Geiger M., Li R.H., Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv. Drug Deliv. Rev. 2003, 55:1613-1629.
11. Fischer J., Kolk A., Wolfart S., Pautke C., Warnke P.H., Plank C., Smeets R. Future of local bone regeneration-protein versus gene therapy. J. Craniomaxillofac. Surg. 2011, 39:54-64.
12. Guldberg R.E. Spatiotemporal delivery strategies for promoting musculoskeletal tissue regeneration. J. Bone Miner. Res. 2009, 24:1507-1511.
13. Li R.H., Wozney J.M. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. 2001, 19:255-265.
14. Hollinger J.O., Schmitt J.M., Buck D.C., Shannon R., Joh S.P., Zegzula H.D., Wozney J. Recombinant human bone morphogenetic protein-2 and collagen for bone regeneration. J. Biomed. Mater. Res. 1998, 43:356-364.
15. Friedlaender G.E., Perry C.R., Cole J.D., Cook S.D., Cierny G., Muschler G.F., Zych G.A., Calhoun J.H., LaForte A.J., Yin S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J. Bone Joint Surg. Am. 2001, 83-A(Suppl. 1):S151-S158.
16. Gautschi O.P., Frey S.P., Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J. Surg. 2007, 77:626-631.
17. Giannoudis P.V., Dinopoulos H.T. BMPs: options, indications, and effectiveness. J. Orthop. Trauma 2010, 24(Suppl. 1):S9-S16.
18. Einhorn T.A. Clinical applications of recombinant human BMPs: early experience and future development. J. Bone Joint Surg. Am. 2003, 85-A(Suppl. 3):82-88.
19. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011, 11:471-491.
20. Luginbuehl V., Meinel L., Merkle H.P., Gander B. Localized delivery of growth factors for bone repair. Eur. J. Pharm. Biopharm. 2004, 58:197-208.
21. Simons M., Ware J.A. Therapeutic angiogenesis in cardiovascular disease. Nat. Rev. Drug Discov. 2003, 2:863-871.
22. Chen R.R., Mooney D.J. Polymeric growth factor delivery strategies for tissue engineering. Pharm. Res. 2003, 20:1103-1112.
23. Elisseeff J., Puleo C., Yang F., Sharma B. Advances in skeletal tissue engineering with hydrogels. Orthod. Craniofac. Res. 2005, 8:150-161.
24. Lutolf M.P., Weber F.E., Schmoekel H.G., Schense J.C., Kohler T., Muller R., Hubbell J.A. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat. Biotechnol. 2003, 21:513-518.
25. Place E.S., Evans N.D., Stevens M.M. Complexity in biomaterials for tissue engineering. Nat. Mater. 2009, 8:457-470.
26. Daley W.P., Peters S.B., Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J. Cell Sci. 2008, 121:255-264.
27. Bissell M.J., Aggeler J. Dynamic reciprocity: how do extracellular matrix and hormones direct gene expression?. Prog. Clin. Biol. Res. 1987, 249:251-262.
28. Bissell M.J., Hall H.G., Parry G. How does the extracellular matrix direct gene expression?. J. Theor. Biol. 1982, 99:31-68.
29. Kamphaus G.D., Colorado P.C., Panka D.J., Hopfer H., Ramchandran R., Torre A., Maeshima Y., Mier J.W., Sukhatme V.P., Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 2000, 275:1209-1215.
30. Maeshima Y., Manfredi M., Reimer C., Holthaus K.A., Hopfer H., Chandamuri B.R., Kharbanda S., Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 2001, 276:15240-15248.
31. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
32. Cheresh D.A., Stupack D.G. Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene 2008, 27:6285-6298.
33. Allori A.C., Sailon A.M., Warren S.M. Biological basis of bone formation, remodeling, and repair-part II: extracellular matrix. Tissue Eng. Part B Rev. 2008, 14:275-283.
34. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
35. Hacker U., Nybakken K., Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat. Rev. Mol. Cell Biol. 2005, 6:530-541.
36. Macri L., Silverstein D., Clark R.A. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv. Drug Deliv. Rev. 2007, 59:1366-1381.
37. Gandhi N.S., Mancera R.L. Free energy calculations of glycosaminoglycan-protein interactions. Glycobiology 2009, 19:1103-1115.
38. Maciag T., Mehlman T., Friesel R., Schreiber A.B. Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science 1984, 225:932-935.
39. McCaffrey T.A., Falcone D.J., Du B. Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J. Cell. Physiol. 1992, 152:430-440.
40. Nugent M.A., Edelman E.R. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. Biochemistry 1992, 31:8876-8883.
41. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., Ehler E., Kakkar V.V., Stalmans I., Mattot V., Perriard J.C., Dewerchin M., Flameng W., Nagy A., Lupu F., Moons L., Collen D., D'Amore P.A., Shima D.T. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 1999, 5:495-502.
42. Ruhrberg C., Gerhardt H., Golding M., Watson R., Ioannidou S., Fujisawa H., Betsholtz C., Shima D.T. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 2002, 16:2684-2698.
43. Stalmans I., Ng Y.S., Rohan R., Fruttiger M., Bouche A., Yuce A., Fujisawa H., Hermans B., Shani M., Jansen S., Hicklin D., Anderson D.J., Gardiner T., Hammes H.P., Moons L., Dewerchin M., Collen D., Carmeliet P., D'Amore P.A. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 2002, 109:327-336.
44. Grunstein J., Masbad J.J., Hickey R., Giordano F., Johnson R.S. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol. Cell. Biol. 2000, 20:7282-7291.
45. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
46. Engel J. EGF-like domains in extracellular matrix proteins: localized signals for growth and differentiation?. FEBS Lett. 1989, 251:1-7.
47. Iyer A.K., Tran K.T., Borysenko C.W., Cascio M., Camacho C.J., Blair H.C., Bahar I., Wells A. Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity. J. Cell. Physiol. 2007, 211:748-758.
48. Panayotou G., End P., Aumailley M., Timpl R., Engel J. Domains of laminin with growth-factor activity. Cell 1989, 56:93-101.
49. Schenk S., Hintermann E., Bilban M., Koshikawa N., Hojilla C., Khokha R., Quaranta V. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J. Cell Biol. 2003, 161:197-209.
50. Mohammadi M., Olsen S.K., Goetz R. A protein canyon in the FGF-FGF receptor dimer selects from an a la carte menu of heparan sulfate motifs. Curr. Opin. Struct. Biol. 2005, 15:506-516.
51. Ramirez F., Sakai L.Y., Rifkin D.B., Dietz H.C. Extracellular microfibrils in development and disease. Cell. Mol. Life Sci. 2007, 64:2437-2446.
52. Ramirez F., Dietz H.C. Extracellular microfibrils in vertebrate development and disease processes. J. Biol. Chem. 2009, 284:14677-14681.
53. Comoglio P.M., Boccaccio C., Trusolino L. Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr. Opin. Cell Biol. 2003, 15:565-571.
54. Streuli C.H., Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem. J. 2009, 418:491-506.
55. Schneller M., Vuori K., Ruoslahti E. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J. 1997, 16:5600-5607.
56. Scaffidi A.K., Petrovic N., Moodley Y.P., Fogel-Petrovic M., Kroeger K.M., Seeber R.M., Eidne K.A., Thompson P.J., Knight D.A. alpha(v)beta(3) Integrin interacts with the transforming growth factor beta (TGFbeta) type II receptor to potentiate the proliferative effects of TGFbeta1 in living human lung fibroblasts. J. Biol. Chem. 2004, 279:37726-37733.
57. Soldi R., Mitola S., Strasly M., Defilippi P., Tarone G., Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999, 18:882-892.
58. Moro L., Venturino M., Bozzo C., Silengo L., Altruda F., Beguinot L., Tarone G., Defilippi P. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 1998, 17:6622-6632.
59. Falcioni R., Antonini A., Nistico P., Di Stefano S., Crescenzi M., Natali P.G., Sacchi A. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp. Cell Res. 1997, 236:76-85.
60. Trusolino L., Bertotti A., Comoglio P.M. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001, 107:643-654.
61. Giancotti F.G., Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu. Rev. Cell Dev. Biol. 2003, 19:173-206.
62. Kim S.H., Turnbull J., Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 2011, 209:139-151.
63. Martino M.M., Tortelli F., Mochizuki M., Traub S., Ben-David D., Kuhn G.A., Muller R., Livne E., Eming S.A., Hubbell J.A. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci. Transl. Med. 2011, 3. 100ra189.
64. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J. Cell. Biochem. 2003, 88:873-884.
65. Everts V., Delaisse J.M., Korper W., Niehof A., Vaes G., Beertsen W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J. Cell. Physiol. 1992, 150:221-231.
66. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., Bertoncello I., Drake F., Zavarselk S., Tellis I., Hertzog P., Debouck C., Kola I. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 1999, 14:1654-1663.
67. Farley J.R., Tarbaux N., Murphy L.A., Masuda T., Baylink D.J. In vitro evidence that bone formation may be coupled to resorption by release of mitogen(s) from resorbing bone. Metabolism 1987, 36:314-321.
68. Feng X., McDonald J.M. Disorders of bone remodeling. Annu. Rev. Pathol. 2011, 6:121-145.
69. Little D.G., Ramachandran M., Schindeler A. The anabolic and catabolic responses in bone repair. J. Bone Joint Surg. Br. 2007, 89:425-433.
70. Yu Y.Y., Lieu S., Lu C., Miclau T., Marcucio R.S., Colnot C. Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair. Bone 2010, 46:841-851.
71. Einhorn T.A. The cell and molecular biology of fracture healing. Clin. Orthop. Relat. Res. 1998, S7-S21.
72. Schindeler A., McDonald M.M., Bokko P., Little D.G. Bone remodeling during fracture repair: the cellular picture. Semin. Cell Dev. Biol. 2008, 19:459-466.
73. Bolander M.E. Regulation of fracture repair by growth factors. Proc. Soc. Exp. Biol. Med. 1992, 200:165-170.
74. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996, 271:10079-10086.
75. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
76. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
77. Wozney J.M. The bone morphogenetic protein family and osteogenesis. Mol. Reprod. Dev. 1992, 32:160-167.
78. Molin D., Post M.J. Therapeutic angiogenesis in the heart: protect and serve. Curr. Opin. Pharmacol. 2007, 7:158-163.
79. Barnes G.L., Kakar S., Vora S., Morgan E.F., Gerstenfeld L.C., Einhorn T.A. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J. Bone Joint Surg. Am. 2008, 90(Suppl. 1):120-127.
80. Eppler S.M., Combs D.L., Henry T.D., Lopez J.J., Ellis S.G., Yi J.H., Annex B.H., McCluskey E.R., Zioncheck T.F. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther. 2002, 72:20-32.
81. Lee K., Silva E.A., Mooney D.J. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J. R. Soc. Interface 2011, 8:153-170.
82. Saik J.E., Gould D.J., Watkins E.M., Dickinson M.E., West J.L. Covalently immobilized platelet-derived growth factor-BB promotes angiogenesis in biomimetic poly(ethylene glycol) hydrogels. Acta Biomater. 2011, 7:133-143.
83. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6:389-395.
84. Lee R.J., Springer M.L., Blanco-Bose W.E., Shaw R., Ursell P.C., Blau H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000, 102:898-901.
85. Byrne M.E., Park K., Peppas N.A. Molecular imprinting within hydrogels. Adv. Drug Deliv. Rev. 2002, 54:149-161.
86. Silva A.K., Richard C., Bessodes M., Scherman D., Merten O.W. Growth factor delivery approaches in hydrogels. Biomacromolecules 2009, 10:9-18.
87. Hubbell J.A. Materials as morphogenetic guides in tissue engineering. Curr. Opin. Biotechnol. 2003, 14:551-558.
88. Bentz H., Schroeder J.A., Estridge T.D. Improved local delivery of TGF-beta2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol. J. Biomed. Mater. Res. 1998, 39:539-548.
89. Koch S., Yao C., Grieb G., Prevel P., Noah E.M., Steffens G.C. Enhancing angiogenesis in collagen matrices by covalent incorporation of VEGF. J. Mater. Sci. Mater. Med. 2006, 17:735-741.
90. Mann B.K., Schmedlen R.H., West J.L. Tethered-TGF-beta increases extracellular matrix production of vascular smooth muscle cells. Biomaterials 2001, 22:439-444.
91. DeLong S.A., Moon J.J., West J.L. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials 2005, 26:3227-3234.
92. Gobin A.S., West J.L. Effects of epidermal growth factor on fibroblast migration through biomimetic hydrogels. Biotechnol. Prog. 2003, 19:1781-1785.
93. Saik J.E., Gould D.J., Keswani A.H., Dickinson M.E., West J.L. Biomimetic hydrogels with immobilized ephrinA1 for therapeutic angiogenesis. Biomacromolecules 2011, 12:2715-2722.
94. He X., Ma J., Jabbari E. Effect of grafting RGD and BMP-2 protein-derived peptides to a hydrogel substrate on osteogenic differentiation of marrow stromal cells. Langmuir 2008, 24:12508-12516.
95. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., Berthold W., Graves M. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 2001, 12:195-202.
96. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22:405-417.
97. Zisch A.H., Lutolf M.P., Ehrbar M., Raeber G.P., Rizzi S.C., Davies N., Schmokel H., Bezuidenhout D., Djonov V., Zilla P., Hubbell J.A. Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J. 2003, 17:2260-2262.
98. Sakiyama S.E., Schense J.C., Hubbell J.A. Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering. FASEB J. 1999, 13:2214-2224.
99. Sakiyama-Elbert S.E., Panitch A., Hubbell J.A. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J. 2001, 15:1300-1302.
100. Schense J.C., Hubbell J.A. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug. Chem. 1999, 10:75-81.
101. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. Covalently conjugated VEGF-fibrin matrices for endothelialization. J. Control. Release 2001, 72:101-113.
102. Ehrbar M., Djonov V.G., Schnell C., Tschanz S.A., Martiny-Baron G., Schenk U., Wood J., Burri P.H., Hubbell J.A., Zisch A.H. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res. 2004, 94:1124-1132.
103. Ehrbar M., Metters A., Zammaretti P., Hubbell J.A., Zisch A.H. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J. Control. Release 2005, 101:93-109.
104. Ehrbar M., Zeisberger S.M., Raeber G.P., Hubbell J.A., Schnell C., Zisch A.H. The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials 2008, 29:1720-1729.
105. Weber C.C., Cai H., Ehrbar M., Kubota H., Martiny-Baron G., Weber W., Djonov V., Weber E., Mallik A.S., Fussenegger M., Frei K., Hubbell J.A., Zisch A.H. Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization. J. Biol. Chem. 2005, 280:22445-22453.
106. Zisch A.H., Zeisberger S.M., Ehrbar M., Djonov V., Weber C.C., Ziemiecki A., Pasquale E.B., Hubbell J.A. Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2. Biomaterials 2004, 25:3245-3257.
107. Hall H., Djonov V., Ehrbar M., Hoechli M., Hubbell J.A. Heterophilic interactions between cell adhesion molecule L1 and alphavbeta3-integrin induce HUVEC process extension in vitro and angiogenesis in vivo. Angiogenesis 2004, 7:213-223.
108. Hall H., Hubbell J.A. Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3-integrin and activating VEGF-R2. Microvasc. Res. 2004, 68:169-178.
109. Luhmann T., Hanseler P., Grant B., Hall H. The induction of cell alignment by covalently immobilized gradients of the 6th Ig-like domain of cell adhesion molecule L1 in 3D-fibrin matrices. Biomaterials 2009, 30:4503-4512.
110. Pittier R., Sauthier F., Hubbell J.A., Hall H. Neurite extension and in vitro myelination within three-dimensional modified fibrin matrices. J. Neurobiol. 2005, 63:1-14.
111. Arrighi I., Mark S., Alvisi M., von Rechenberg B., Hubbell J.A., Schense J.C. Bone healing induced by local delivery of an engineered parathyroid hormone prodrug. Biomaterials 2009, 30:1763-1771.
112. Lorentz K.M., Yang L., Frey P., Hubbell J.A. Engineered insulin-like growth factor-1 for improved smooth muscle regeneration. Biomaterials 2012, 33:494-503.
113. Schmoekel H.G., Weber F.E., Schense J.C., Gratz K.W., Schawalder P., Hubbell J.A. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol. Bioeng. 2005, 89:253-262.
114. Geer D.J., Swartz D.D., Andreadis S.T. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. Am. J. Pathol. 2005, 167:1575-1586.
115. Ehrbar M., Rizzi S.C., Schoenmakers R.G., Miguel B.S., Hubbell J.A., Weber F.E., Lutolf M.P. Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions. Biomacromolecules 2007, 8:3000-3007.
116. Ehrbar M., Rizzi S.C., Hlushchuk R., Djonov V., Zisch A.H., Hubbell J.A., Weber F.E., Lutolf M.P. Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials 2007, 28:3856-3866.
117. Lin C.C., Anseth K.S. Controlling affinity binding with peptide-functionalized poly(ethylene glycol) hydrogels. Adv. Funct. Mater. 2009, 19:2325.
118. Uebersax L., Merkle H.P., Meinel L. Biopolymer-based growth factor delivery for tissue repair: from natural concepts to engineered systems. Tissue Eng. Part B Rev. 2009, 15:263-289.
119. Wissink M.J., Beernink R., Scharenborg N.M., Poot A.A., Engbers G.H., Beugeling T., van Aken W.G., Feijen J. Endothelial cell seeding of (heparinized) collagen matrices: effects of bFGF pre-loading on proliferation (after low density seeding) and pro-coagulant factors. J. Control. Release 2000, 67:141-155.
120. Grieb G., Groger A., Piatkowski A., Markowicz M., Steffens G.C., Pallua N. Tissue substitutes with improved angiogenic capabilities: an in vitro investigation with endothelial cells and endothelial progenitor cells. Cells Tissues Organs 2010, 191:96-104.
121. Markowicz M., Heitland A., Steffens G.C., Pallua N. Effects of modified collagen matrices on human umbilical vein endothelial cells. Int. J. Artif. Organs 2005, 28:1251-1258.
122. Steffens G.C., Yao C., Prevel P., Markowicz M., Schenck P., Noah E.M., Pallua N. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng. 2004, 10:1502-1509.
123. van Wachem P.B., Plantinga J.A., Wissink M.J., Beernink R., Poot A.A., Engbers G.H., Beugeling T., van Aken W.G., Feijen J., van Luyn M.J. In vivo biocompatibility of carbodiimide-crosslinked collagen matrices: Effects of crosslink density, heparin immobilization, and bFGF loading. J. Biomed. Mater. Res. 2001, 55:368-378.
124. Wissink M.J., Beernink R., Pieper J.S., Poot A.A., Engbers G.H., Beugeling T., van Aken W.G., Feijen J. Binding and release of basic fibroblast growth factor from heparinized collagen matrices. Biomaterials 2001, 22:2291-2299.
125. Bladergroen B.A., Siebum B., Siebers-Vermeulen K.G., Van Kuppevelt T.H., Poot A.A., Feijen J., Figdor C.G., Torensma R. In vivo recruitment of hematopoietic cells using stromal cell-derived factor 1 alpha-loaded heparinized three-dimensional collagen scaffolds. Tissue Eng. Part A 2009, 15:1591-1599.
126. Freudenberg U., Hermann A., Welzel P.B., Stirl K., Schwarz S.C., Grimmer M., Zieris A., Panyanuwat W., Zschoche S., Meinhold D., Storch A., Werner C. A star-PEG-heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases. Biomaterials 2009, 30:5049-5060.
127. Nie T., Baldwin A., Yamaguchi N., Kiick K.L. Production of heparin-functionalized hydrogels for the development of responsive and controlled growth factor delivery systems. J. Control. Release 2007, 122:287-296.
128. Yamaguchi N., Zhang L., Chae B.S., Palla C.S., Furst E.M., Kiick K.L. Growth factor mediated assembly of cell receptor-responsive hydrogels. J. Am. Chem. Soc. 2007, 129:3040-3041.
129. Sakiyama-Elbert S.E., Hubbell J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control. Release 2000, 65:389-402.
130. Sakiyama-Elbert S.E., Hubbell J.A. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J. Control. Release 2000, 69:149-158.
131. Johnson P.J., Parker S.R., Sakiyama-Elbert S.E. Fibrin-based tissue engineering scaffolds enhance neural fiber sprouting and delay the accumulation of reactive astrocytes at the lesion in a subacute model of spinal cord injury. J. Biomed. Mater. Res. A 2010, 92:152-163.
132. Johnson P.J., Parker S.R., Sakiyama-Elbert S.E. Controlled release of neurotrophin-3 from fibrin-based tissue engineering scaffolds enhances neural fiber sprouting following subacute spinal cord injury. Biotechnol. Bioeng. 2009, 104:1207-1214.
133. Johnson P.J., Tatara A., Shiu A., Sakiyama-Elbert S.E. Controlled release of neurotrophin-3 and platelet-derived growth factor from fibrin scaffolds containing neural progenitor cells enhances survival and differentiation into neurons in a subacute model of SCI. Cell Transplant. 2010, 19:89-101.
134. Taylor S.J., McDonald J.W., Sakiyama-Elbert S.E. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury. J. Control. Release 2004, 98:281-294.
135. Taylor S.J., Rosenzweig E.S., McDonald J.W., Sakiyama-Elbert S.E. Delivery of neurotrophin-3 from fibrin enhances neuronal fiber sprouting after spinal cord injury. J. Control. Release 2006, 113:226-235.
136. Taylor S.J., Sakiyama-Elbert S.E. Effect of controlled delivery of neurotrophin-3 from fibrin on spinal cord injury in a long term model. J. Control. Release 2006, 116:204-210.
137. Sakiyama-Elbert S.E., Das R., Gelberman R.H., Harwood F., Amiel D., Thomopoulos S. Controlled-release kinetics and biologic activity of platelet-derived growth factor-BB for use in flexor tendon repair. J. Hand Surg. Am. 2008, 33:1548-1557.
138. Thomopoulos S., Zaegel M., Das R., Harwood F.L., Silva M.J., Amiel D., Sakiyama-Elbert S., Gelberman R.H. PDGF-BB released in tendon repair using a novel delivery system promotes cell proliferation and collagen remodeling. J. Orthop. Res. 2007, 25:1358-1368.
139. Pike D.B., Cai S., Pomraning K.R., Firpo M.A., Fisher R.J., Shu X.Z., Prestwich G.D., Peattie R.A. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 2006, 27:5242-5251.
140. Riley C.M., Fuegy P.W., Firpo M.A., Shu X.Z., Prestwich G.D., Peattie R.A. Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. Biomaterials 2006, 27:5935-5943.
141. Liu Y., Cai S., Shu X.Z., Shelby J., Prestwich G.D. Release of basic fibroblast growth factor from a crosslinked glycosaminoglycan hydrogel promotes wound healing. Wound Repair Regen 2007, 15:245-251.
142. Cai S., Liu Y., Zheng Shu X., Prestwich G.D. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 2005, 26:6054-6067.
143. Zhao J., Zhang N., Prestwich G.D., Wen X. Recruitment of endogenous stem cells for tissue repair. Macromol. Biosci. 2008, 8:836-842.
144. Hosack L.W., Firpo M.A., Scott J.A., Prestwich G.D., Peattie R.A. Microvascular maturity elicited in tissue treated with cytokine-loaded hyaluronan-based hydrogels. Biomaterials 2008, 29:2336-2347.
145. Martino M.M., Hubbell J.A. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J. 2010, 24:4711-4721.
146. Pratt A.B., Weber F.E., Schmoekel H.G., Muller R., Hubbell J.A. Synthetic extracellular matrices for in situ tissue engineering. Biotechnol. Bioeng. 2004, 86:27-36.
147. Albrecht D.R., Tsang V.L., Sah R.L., Bhatia S.N. Photo- and electropatterning of hydrogel-encapsulated living cell arrays. Lab Chip 2005, 5:111-118.
148. Gobaa S., Hoehnel S., Roccio M., Negro A., Kobel S., Lutolf M.P. Artificial niche microarrays for probing single stem cell fate in high throughput. Nat. Methods 2011, 8:949-955.
149. Kobel S., Lutolf M.P. Biomaterials meet microfluidics: building the next generation of artificial niches. Curr. Opin. Biotechnol. 2011, 22:690-697.
150. Sala A., Hanseler P., Ranga A., Lutolf M.P., Voros J., Ehrbar M., Weber F.E. Engineering 3D cell instructive microenvironments by rational assembly of artificial extracellular matrices and cell patterning. Integr. Biol. (Camb) 2011, 3:1102-1111.
151. Lutolf M.P., Blau H.M. Artificial stem cell niches. Adv. Mater. 2009, 21:3255-3268.
152. Kloxin A.M., Kasko A.M., Salinas C.N., Anseth K.S. Photodegradable hydrogels for dynamic tuning of physical and chemical properties. Science 2009, 324:59-63.
153. Tsang V.L., Bhatia S.N. Three-dimensional tissue fabrication. Adv. Drug Deliv. Rev. 2004, 56:1635-1647.
154. Grayson W.L., Martens T.P., Eng G.M., Radisic M., Vunjak-Novakovic G. Biomimetic approach to tissue engineering. Semin. Cell Dev. Biol. 2009, 20:665-673.
155. Shen Y.H., Shoichet M.S., Radisic M. Vascular endothelial growth factor immobilized in collagen scaffold promotes penetration and proliferation of endothelial cells. Acta Biomater. 2008, 4:477-489.
156. Zhang G., Nakamura Y., Wang X., Hu Q., Suggs L.J., Zhang J. Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart. Tissue Eng. 2007, 13:2063-2071.
157. Leipzig N.D., Xu C., Zahir T., Shoichet M.S. Functional immobilization of interferon-gamma induces neuronal differentiation of neural stem cells. J. Biomed. Mater. Res. A 2010, 93:625-633.
158. Seliktar D., Zisch A.H., Lutolf M.P., Wrana J.L., Hubbell J.A. MMP-2 sensitive, VEGF-bearing bioactive hydrogels for promotion of vascular healing. J. Biomed. Mater. Res. A 2004, 68:704-716.
159. Lorentz K.M., Kontos S., Frey P., Hubbell J.A. Engineered aprotinin for improved stability of fibrin biomaterials. Biomaterials 2011, 32:430-438.
160. Tae G., Scatena M., Stayton P.S., Hoffman A.S. PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor. J. Biomater. Sci. Polym. Ed. 2006, 17:187-197.
161. Zhang L., Furst E.M., Kiick K.L. Manipulation of hydrogel assembly and growth factor delivery via the use of peptide-polysaccharide interactions. J. Control. Release 2006, 114:130-142.
162. Yamaguchi N., Kiick K.L. Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels. Biomacromolecules 2005, 6:1921-1930.
163. Benoit D.S., Anseth K.S. Heparin functionalized PEG gels that modulate protein adsorption for hMSC adhesion and differentiation. Acta Biomater. 2005, 1:461-470.
164. Martinez-Sanz E., Ossipov D.A., Hilborn J., Larsson S., Jonsson K.B., Varghese O.P. Bone reservoir: Injectable hyaluronic acid hydrogel for minimal invasive bone augmentation. J. Control. Release 2011, 152:232-240.
165. Patterson J., Siew R., Herring S.W., Lin A.S., Guldberg R., Stayton P.S. Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration. Biomaterials 2010, 31:6772-6781.
166. Zhao W., Han Q., Lin H., Sun W., Gao Y., Zhao Y., Wang B., Wang X., Chen B., Xiao Z., Dai J. Human basic fibroblast growth factor fused with Kringle4 peptide binds to a fibrin scaffold and enhances angiogenesis. Tissue Eng. Part A 2009, 15:991-998.
167. Zhao W., Han Q., Lin H., Gao Y., Sun W., Zhao Y., Wang B., Chen B., Xiao Z., Dai J. Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin. J. Mol. Med. (Berl.) 2008, 86:1127-1138.
168. Yang Y., Zhao Y., Chen B., Han Q., Sun W., Xiao Z., Dai J. Collagen-binding human epidermal growth factor promotes cellularization of collagen scaffolds. Tissue Eng. Part A 2009, 15:3589-3596.
169. Sun W., Lin H., Xie H., Chen B., Zhao W., Han Q., Zhao Y., Xiao Z., Dai J. Collagen membranes loaded with collagen-binding human PDGF-BB accelerate wound healing in a rabbit dermal ischemic ulcer model. Growth Factors 2007, 25:309-318.
170. Han Q., Sun W., Lin H., Zhao W., Gao Y., Zhao Y., Chen B., Xiao Z., Hu W., Li Y., Yang B., Dai J. Linear ordered collagen scaffolds loaded with collagen-binding brain-derived neurotrophic factor improve the recovery of spinal cord injury in rats. Tissue Eng. Part A 2009, 15:2927-2935.